Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB1 | P20618 | 11/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 10/20 | 0.40 |
| ▸ | PSMB2 | P49721 | 7/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6979246 | 0.84 | GAA (0.43) | PSMB1PSMB5KDM4ELMNA | |
| SCHEMBL6976865 | 0.84 | PSMB1 (0.36) | PSMB1PSMB5PSMB2KDM4ELMNA | |
| SCHEMBL13151498 | 0.83 | PSMB1 (0.41) | PSMB1PSMB5PSMB2KDM4ELMNA | |
| SCHEMBL9975277 | 0.83 | PSMB1 (0.41) | PSMB1PSMB5PSMB2KDM4ELMNA | |
| Hydrochloric Acid SCHEMBL28035282 | 0.81 | PSMB1 (0.41) | PSMB1PSMB5PSMB2KDM4ELMNA | |
| SCHEMBL6978681 | 0.81 | PSMB1 (0.39) | PSMB1PSMB5PSMB2KDM4ELMNA | |
| SCHEMBL6978964 | 0.81 | PSMB1 (0.35) | PSMB1PSMB5PSMB2KDM4ELTA4H | |
| SCHEMBL6979435 | 0.80 | TACR1 (0.35) | — | |
| SCHEMBL16837520 | 0.79 | PSMB1 (0.38) | PSMB1PSMB5PSMB2KDM4E | |
| SCHEMBL9944262 | 0.79 | PSMB1 (0.43) | PSMB1PSMB5PSMB2KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149707-A1 | ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | OSCOTEC INC. (KR) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149707-A1 | ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | HIF1A, HIF1AN, EGLN3 | PSMB1 302/4885PSMB5 585/4885PSMB2 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.